scholarly journals Metabolic syndrome and obesity as factors of good procnostic oncology in women in post-menopause with recent diagnosis of breast cancer

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Andre Hideo Motoki ◽  
Daniel de Araújo Brito Buttros ◽  
Heloisa Maria de Luca Vespoli ◽  
Eduardo Carvalho Pessoa ◽  
Eliana Aguiar Petri Nahas
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Postmenopausal Women ◽  
Fat Deposition ◽  
University Hospital ◽  
Control Group ◽  
Ki 67 ◽  
Luminal B ◽  
Central Fat ◽  
Her 2

Objective: To evaluate the association between metabolic syndrome (MS), obesity, and central fat deposition with the immunohistochemical profile (IHC) of breast cancer (BC) in postmenopausal women. Methods: A comparative cross-sectional clinical study was carried out with 63 women with recent BC and MS, compared to 126 women with recent BC, without MS (control group). Inclusion criteria were: women aged 45-75 years, amenorrhea >12 months, without previous cancer treatment, attended at a University Hospital. The groups were matched for age, time since menopause, and body mass index (BMI), in the proportion of 1 case for 2 controls, according to the sample calculation of at least 186 women in their entirety. Clinical and anthropometric data were collected; tumor size and grade and the IHC profile (ER, PR, HER2, and Ki67). By IHC convention, tumors were grouped into five subtypes: Luminal A (ER+, PR+, HER-2 -, and Ki-67 <14%); Luminal B HER-2 - (ER+, PR+ or -, HER-2 -, and Ki-67≥14%); Luminal B HER-2+ (ER+, PR+ or -, HER-2+, and any Ki-67); Non-luminal HER-2 (ER-, PR-, HER2+, and any Ki-67); and Triple-negative (ER-, PR-, HER2-, and any Ki-67). Women with three or more diagnostic criteria were considered with MS: waist circumference (WC)>88 cm; TG≥150 mg/dL; HDL cholesterol<50 mg/dL; blood pressure ≥130/85 mmHg; glucose ≥100 mg/dL. For statistical analysis, the Student’s t-test, Gamma Distribution, χ2 test and logistic regression (odds ratio–OR) were used. Results: Among the participating women, the mean age, time since menopause and BMI were: 59.0±10.6 years, 11.4±9.6 years, and 28.5±5.5 kg/m2, respectively; there was no statistical difference in the comparison between the groups. Women with MS had a higher occurrence of tumors ≤2cm when compared to those without MS (49.2 vs. 31.8%, respectively) (p=0.038). Women with MS had a higher incidence of tumors with PR-positive (p=0.046), HER2-negative (p=0.038), when compared to women without MS (79.4 vs. 65.8% and 44.5 vs. 27.8%, respectively). In obese patients (BMI≥30 kg/m2), a higher proportion of HER2 negative tumors (p=0.047) was observed when compared to non-obese women (43.9 vs. 27.7%, respectively). In the multivariate analysis, a higher risk for tumors of the Luminal B HER-2 negative subtype was observed among women with MS (OR 2.00, 95%CI 1.03‒3.89), obese (OR 2.03, 95%CI 1.06‒3.90), and with central deposition of fat (OR 1.96, 95%CI 1.01‒4.03). Conclusion: Metabolic syndrome, obesity, and central fat deposition correlate with factors of good prognosis for breast cancer, such as tumors ≤2 cm, PR+ and HER2-, in postmenopausal women.

Immunohistochemical Profiles of Breast Cancer Patients at MRCCC Siloam Semanggi Hospital in 2018

2021 ◽  
Vol 11 (5) ◽  
pp. 392-400
Author(s):  
Fajar Lamhot Gultom ◽  
Marliana Nurprilinda ◽  
Ryani Nur Cahyaning Hutami
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtype ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Proliferation Markers ◽  
Luminal B ◽  
Cancer Subtype ◽  
Anatomy Laboratory ◽  
Grade Ii ◽  
Her 2

Immunohistochemistry examination (IHC) is one of the additional tests to diagnose and determine breast cancer subtype. IHC examination is a method to check intracellular protein using a monoclonal and polyclonal antibody to detect the antigen in tissue. IHC examination determined by hormone receptor markers (ER and PR), HER-2/Neu expression, and apoptotic and proliferation markers (Ki-67 and p53) can be used to determine therapy and prognosis. This study aims to determine the hormonal status of breast cancer patient at Siloam Semanggi Hospital in 2018, in the form of age, gender, pathology diagnose, and the result of IHC (ER, PR, HER2, and Ki-67). This study is a retrospective descriptive study using pathological anatomy laboratory results of breast cancer in MRCCC Siloam Semanggi Hospital and 208 patients following inclusion and exclusion criteria. The result obtained is that the age group with the highest frequency is 50-59 years, with 34.1%. The highest frequency by gender is a woman with 99.5%. Carcinoma mammae NST with grade II and III was found in 38.0% of patients. The hormonal receptor with ER and PR positive was found in 51.0% of patients. HER2 expression negative was found in 56.7% of patients. High proliferation Ki-67 was found in 82.7% of patients. Luminal B with HER2 negative subtype was found in 32.2% of patients. Patients in 50-59 years with Luminal B with HER2 negative subtype was found in 26 patients. Patients in carcinoma mammae NST with grade II with Luminal B with HER2 negative subtype was found in 27 patients. Keywords: Breast cancer, pathologic anatomy, immunohistochemistry, breast cancer subtype

scholarly journals Apparent diffusion coefficient cannot predict molecular subtype and lymph node metastases in invasive breast cancer: a multicenter analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Alexey Surov ◽  
Yun-Woo Chang ◽  
Lihua Li ◽  
Laura Martincich ◽  
Savannah C. Partridge ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diffusion Coefficient ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Apparent Diffusion ◽  
Adc Values ◽  
Her 2

Abstract Background Radiological imaging plays a central role in the diagnosis of breast cancer (BC). Some studies suggest MRI techniques like diffusion weighted imaging (DWI) may provide further prognostic value by discriminating between tumors with different biologic characteristics including receptor status and molecular subtype. However, there is much contradictory reported data regarding such associations in the literature. The purpose of the present study was to provide evident data regarding relationships between quantitative apparent diffusion coefficient (ADC) values on DWI and pathologic prognostic factors in BC. Methods Data from 5 centers (661 female patients, mean age, 51.4 ± 10.5 years) were acquired. Invasive ductal carcinoma (IDC) was diagnosed in 625 patients (94.6%) and invasive lobular carcinoma in 36 cases (5.4%). Luminal A carcinomas were diagnosed in 177 patients (28.0%), luminal B carcinomas in 279 patients (44.1%), HER 2+ carcinomas in 66 cases (10.4%), and triple negative carcinomas in 111 patients (17.5%). The identified lesions were staged as T1 in 51.3%, T2 in 43.0%, T3 in 4.2%, and as T4 in 1.5% of the cases. N0 was found in 61.3%, N1 in 33.1%, N2 in 2.9%, and N3 in 2.7%. ADC values between different groups were compared using the Mann–Whitney U test and by the Kruskal-Wallis H test. The association between ADC and Ki 67 values was calculated by Spearman’s rank correlation coefficient. Results ADC values of different tumor subtypes overlapped significantly. Luminal B carcinomas had statistically significant lower ADC values compared with luminal A (p = 0.003) and HER 2+ (p = 0.007) lesions. No significant differences of ADC values were observed between luminal A, HER 2+ and triple negative tumors. There were no statistically significant differences of ADC values between different T or N stages of the tumors. Weak statistically significant correlation between ADC and Ki 67 was observed in luminal B carcinoma (r = − 0.130, p = 0.03). In luminal A, HER 2+ and triple negative tumors there were no significant correlations between ADC and Ki 67. Conclusion ADC was not able to discriminate molecular subtypes of BC, and cannot be used as a surrogate marker for disease stage or proliferation activity.

Association of breast cancer and diabetes mellitus in Korean postmenopausal women

2020 ◽  
Author(s):  
Boram Kim ◽  
Jee Hye Han ◽  
Hee Yong Kwak ◽  
Kil Young Kwon ◽  
Junghwan Kim
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
University Hospital ◽  
Control Group ◽  
Breast Clinic ◽  
Cancer Group ◽  
Increased Risk

Abstract Background: Diabetes mellitus has been associated with an increased risk of breast cancer. This association is, however, controversial, and not elucidated in Asia. This study aimed to determine the association between diabetes mellitus and breast cancer risk in Korean women.Methods: This retrospective study included subjects who underwent an ultrasound-localized needle-extracted biopsy to investigate questionable breast findings at the Eulji University Hospital breast clinic in Seoul, Korea, between 2000 and 2019. The medical records of the participants were reviewed to determine their age, diabetic status, and breast pathology findings. The participants were categorized into two groups, namely, the control group, that included those with benign breast disease; and, the breast cancer group. Logistic regression analyses were performed to assess the association between diabetes and breast cancer amongst pre- and post-menopausal participants.Results: A total of 1268 participants were included in this analysis. We found that diabetes was significantly associated with an increased odds of breast cancer (odds ratio [OR] 2.24; 95% confidence interval [CI], 1.76 to 2.84). Additionally, postmenopausal participants (aged ≥ 50 years) showed increased odds for breast cancer (OR 4.32; 95% CI, 3.37 to 5.53). The association between diabetes and breast cancer was significant, after adjusting for age, in the postmenopausal group (adjusted OR [aOR] 1.60; 95% CI, 1.09 to 2.35), but was not significant in the premenopausal group (aOR 1.10; 95% CI, 0.76 to 1.60).Conclusion: Diabetes was associated with increased odds of breast cancer compared to benign breast disease in postmenopausal women in Korea.

scholarly journals The prognostic link between metabolic syndrome and the different breast cancer molecular subtypes: a case control study.

2020 ◽  
Author(s):  
Yi zuo Chen ◽  
Yu ying Zhou ◽  
En dong Chen ◽  
Di shuang Hu ◽  
Xuan Shao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Molecular Subtypes ◽  
Molecular Heterogeneity ◽  
Luminal A ◽  
Luminal B ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Her 2

Abstract Background Metabolic syndrome (MetS) is an important factor related to the poor prognosis of breast cancer (BC). Molecular heterogeneity in the tumor may affect the consequence of BC. The main purpose of this study was to assess the prognostic link between MetS and the different BC molecular subtypes. Methods A total of 960 patients with BC were recruited from January 2010 to June 2014. The relationship between MetS and disease prognosis was assessed by using univariate and multivariate analyses. Results At recruitment, MetS was diagnosed in 199 patients (20.7%). The mean follow-up period was 68.5 months (range, 2–103 months). MetS remained significantly associated with 64% increased risk of recurrence (Hazard Ratio (HR)=1.64; 95% confidence interval (CI) 1.19–2.27, P<0.01) and twofold increased risk of mortality (HR=2.02, 95% CI 1.29–3.16, P<0.01) according to multivariate analysis. By reviewing BC molecular subtypes, the significant associations remained in the subsets of Luminal A (HR=3.1, 95% CI 1.28–4.57, P=0.01), Luminal B (Her2-negative) (HR=3.3, 95% CI 1.31–8.33, P=0.01), and Her-2-positive (non-Luminal) (HR=2.2, 95% CI 1.10–4.39, P=0.03). Conclusions MetS was significantly related to unfavorable prognosis in operable BC, especially in the subgroup of Luminal A. More studies are needed to definitively determine which factors influence the association of MetS with Luminal A subtype.

Correlation between TopIIα and ki-67 expression in tumors of luminal, primary operable breast cancer without HER2/neu overexpression in postmenopausal women as a prognostic factor.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12065-e12065
Author(s):  
Elena P. Ulianova ◽  
Oleg I. Kit ◽  
Vasilij V. Tokmakov ◽  
Iuliana S. Shatova ◽  
Inna A. Novikova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Prognostic Factor ◽  
Postmenopausal Women ◽  
Hormonal Therapy ◽  
Operable Breast Cancer ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Primary Operable Breast Cancer

e12065 Background: Assessment of proliferative activity is important in terms of tumor prognosis. Topoisomerase IIα (TopIIα) and ki-67 are common markers of breast cancer (BC) cell proliferation. The purpose of the study was to assess the correlation between TopIIα and ki-67 expression as a prognostic factor in luminal, primary operable breast cancer without Her 2 neu overexpression in postmenopausal women. Methods: 60 postmenopausal patients with BC (invasive ductal carcinoma) were equally divided into 3 groups: I –luminal A BC, surgical treatment with subsequent radiotherapy and hormonal therapy; II – luminal B BC, surgical treatment with subsequent radiotherapy and hormonal therapy; III – luminal B BC, surgical treatment with subsequent radiotherapy, polychemotherapy and hormonal therapy. Mean age of patients: I – 76.16±3.14 years, II – 65.0±3.91, III – 74.0±2.54 years. Immunohistochemical study was performed with mouse monoclonal ki-67 (Thermo scientific) and TopIIα (Santa Cruz Biotechnology) antibodies using the Reveal Polyvalent HRP-DAB Detection System. Results were analyzed using the STATISTICA 10.0 program (StatSoftInc., USA). Results: The average expression levels of the ki-67 marker in the groups were: I - 12.3±1.4%, II - 15.1±3.1%, III - 37.0±7.1%; TopIIα expression – 3.5±1.6%, 16.0±5.9%, 21.7±6.4%, respectively. The statistically significant Spearman correlation between TopIIα and ki-67 was observed both as general in groups (r = 0.787 at p < 0.001) and in groups with luminal B subtype (groups II and III). Strong positive correlation between TopIIα and ki-67 was registered in groups II (r = 0.941 at p < 0.01) and III (r = 0.864 at p < 0.001) with luminal B subtype. Weak correlation was observed in group I with luminal A subtype (r = 0.477 at p≥0.05). Conclusions: The study revealed a correlative increase in the level of TopIIα with simultaneous overexpression of the ki-67 protein in the studied groups. This indicator can be considered predictive for breast cancer.

Risk factors of local relapses in patients with breast cancer depending on the properties of the primary tumor

2021 ◽  
Vol 43 (3-4) ◽  
pp. 67-73
Author(s):  
O. V. Movchan ◽  
◽  
I. Yu. Bagmut ◽  
I. V. Dosenko ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Primary Tumor ◽  
Main Group ◽  
Control Group ◽  
Histological Structure ◽  
Luminal A ◽  
Luminal B ◽  
Subtype B ◽  
Her 2

Of all a spread of disorders after mastectomy, most frequently we expect about the event of local relapse. The aim – to research the frequency of local relapses in patients with breast carcinoma, considering the subtype properties of the primary tumor. Materials. 6136 patients with breast carcinoma, including 146 patients with LR – main group, and 455 patients without LR – control group. They distributed betting on age, the state of the menstrual function, stage of the disease, histological type of cancer, grade, tumor subtype. Results. In step with the histological structure, ductal carcinoma was commonest. Established the 10-year non-relapse period in main group is longer with Luminal A and Triple-negative subtypes (61 vs 41%) compared to Luminal B and Her-2 / neu type with (3+) amplification (39 % vs 32 % respectively). Conclusions. The stage, histological structure, grade of the tumor does not significantly affect the frequency of local relapses breast cancer patients. The LR is more likely to occur in patients with luminal subtype B, while the littlest frequency of LR occurs with subtype A. Study of the menstrual status of the patient providing local relapses more often arise in women of pre-menopause. Established that the 10-year non-relapse period is that the best in patients with luminal A subtype and TNBC compared to luminal B and HER 2 type with (3+) amplification.

The role of Ki-67 in molecular breast cancer classification.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 583-583
Author(s):  
George Stathopoulos ◽  
Nikolaos Malamos ◽  
Christos Markopoulos ◽  
Athanasios Polychronis ◽  
Sotirios Rigatos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Molecular Classification ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Her 2

583 Background: The Ki-67 antigen was identified the involvement in early steps of polymerase I-dependent ribosomal RNA synthesis. Although it seems that the protein has an important function in cell division, its exact role is still obscure and there is little published work on its overall function. The aim of the present study is to evaluate the contribution of Ki-67 level in respect of tumor recurrence in molecular classified groups of breast cancer patients. Methods: Breast cancer tumor samples were examined for histological confirmation and for estrogen and progesterone receptors, c-erb-B2 expression, proliferation with Grade and Ki-67. Ki-67 was divided in percentage levels, up to 20 and higher than 20%. Immunohistochemistry and Fluorescence in situ hybridization is described for the results of ER, PR, c-erb-B2, Ki-67 biomarkers. Formaldehyde – fixed breast samples were paraffin wax embedded and processed for paraffin sections. The primary antibodies used were: The monoclinal antibody ID5 (M7047, Dakocytomation, Carpinteria, CA) for the detection of ER, the monoclonal anti-PR antibody 636 was used. For the detection of Ki-67 we used monoclonal mouse anti-human Ki-67 MIB-1. The patients molecular classification was Luminal A, Luminal B, Her-2 subtype and basal cell (triple negative). Results: 847 breast cancer patients were recruited. 291 were group as Luminal A, 228 as Luminal B, 221 Her-2 subtype and 107 triple negative. Follow-up was from 3 years to 15 years since diagnosis. It was found that in Luminal A patients, none had Ki-67 higher than 20% and the recurrence was in 10.65%. In Luminal B, the Ki-67 was higher than 20% in 61% of the patients and recurrence 23.68%. In Her-2 subtype >20% Ki-67 was 78.94%, recurrence 17.19%. In triple negative > 20% Ki-67 was in 68.75% and recurrence in 29.90% of the patients. Conclusions: The data presented here indicate that Ki-67 level may be considered as one of valuable biomarkers in breast cancer patients process and recurrence.

scholarly journals Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

2018 ◽  
Vol 6 (6) ◽  
pp. 961-967 ◽  
Author(s):  
Borislav Kondov ◽  
Zvonko Milenkovikj ◽  
Goran Kondov ◽  
Gordana Petrushevska ◽  
Neli Basheska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumour Cell ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Significant Prognostic Factor ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Conditional Gene Expression ◽  
Her 2

INTRODUCTION: The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, with each subtype manifesting certain prognosis and aggression.AIM: Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and Vascular Surgery.MATERIAL AND METHODS: We used the international classification on molecular subtypes of breast cancer which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed during 2014.RESULTS: In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) patients.CONCLUSION: Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer is necessary for the routine histopathological assay.

AGE FEATURES OF MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER

2020 ◽  
Vol 17 (2) ◽  
pp. 187-192
Author(s):  
E.A. Novikova ◽  
◽  
O.V. Kostromina ◽  
D.V. Mikhailov ◽  
S.L. Leontiev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Age Groups ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Age Related ◽  
Age Features ◽  
Immunohistochemical Studies ◽  
Triple Negative Subtype

Aim. The aim of the study was to determine the presence of peculiarities of the age structure in patients with various surrogate molecular biological subtypes of breast cancer. Materials and research methods. This work analyzes the age-related characteristics of the occurrence of molecular biological subtypes in 499 patients with invasive breast cancer. All cases were divided into 5 molecular biological subtypes based on immunohistochemical studies of hormone receptors, Her2, Ki-67. The average age of the patients was 53.4±0.39 years, the predominant group was patients from 50 to 60 years (37.2% of the total). Research results. In patients under 40 years old, the triple negative subtype prevailed (44.8%). Luminal A subtype prevailed in the groups 51-60 years old (more than 41.4%) and over 60 years old (39.7%). Luminal B (Her2-) subtype was equally found in all age groups.

Sign in / Sign up

Export Citation Format

Share Document